Last reviewed · How we verify
FC084CSA tablets — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
FC084CSA tablets (FC084CSA tablets) — FindCure Biosciences (ZhongShan) Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| FC084CSA tablets TARGET | FC084CSA tablets | FindCure Biosciences (ZhongShan) Co., Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- FC084CSA tablets CI watch — RSS
- FC084CSA tablets CI watch — Atom
- FC084CSA tablets CI watch — JSON
- FC084CSA tablets alone — RSS
Cite this brief
Drug Landscape (2026). FC084CSA tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/fc084csa-tablets. Accessed 2026-05-13.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab